Opthea announced the resignation of Dr. Joel Naor, Chief Medical Officer, effective July 15th. Dr. Naor is stepping down to pursue new opportunities and will be replaced by Dr. Kenneth Sall, MD who has been appointed as Opthea’s Senior Medical Advisor. Dr. Sall will assume responsibility for safety oversight of the Opthea’s Phase 3 clinical trials investigating OPT-302, a novel VEGF-C/D ‘trap’ inhibitor, for the treatment of wet age-related macular degeneration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OPT:
- Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
- Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
- Opthea to Present at the Jefferies 2023 Healthcare Conference
- Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
